This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Beckman Research Institute, City of Hope. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Innovations of Tongyuan Xue in Cancer Treatment
Introduction
Tongyuan Xue is a prominent inventor based in Duarte, California. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work primarily focuses on targeted therapies that aim to improve patient outcomes in malignancies.
Latest Patents
Tongyuan Xue holds a patent for "CD33 Targeted Chimeric Antigen Receptor Modified T Cells for Treatment of CD33 Positive Malignancies." This patent represents a breakthrough in the use of modified T cells to specifically target and treat cancers that express the CD33 antigen.
Career Highlights
Xue is affiliated with the Beckman Research Institute at the City of Hope, where he conducts his research. His work has been instrumental in advancing the understanding and treatment of various malignancies, particularly those that are challenging to treat with conventional therapies.
Collaborations
He collaborates with esteemed colleagues, including Lihua Elizabeth Budde and Stephen J. Forman, to further enhance the effectiveness of cancer treatments. Their combined expertise contributes to the innovative approaches being developed at the institute.
Conclusion
Tongyuan Xue's contributions to cancer treatment through his patented innovations highlight the importance of targeted therapies in modern medicine. His work continues to inspire advancements in the field and offers hope for improved patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile